Are you looking for a comprehensive scientific data comparison of Sermorelin with CJC-1295? Learn more about these two potent research peptides in this comprehensive guide, which will explain their possible properties as they were hypothesized by researchers in fields related to:
- growth hormone stimulation
- muscle cell development
- damaged cell restoration
- reduced fatty tissue
Keep reading to learn about the most recent data findings relating the processes, structural differences, possible effects, and other aspects of the two peptides. In addition, we will provide our highly recommended research peptide source, which includes CJC-1295 and Sermorelin.
Sermorelin Peptide: What is it?
In its chemical form, Sermorelin is an analog of growth hormone-releasing hormone (GHRH). Sermorelin, a shortened and amidated (at the C-terminus) variant of the 44-amino acid natural GHRH, is 29 amino acids long. Studies suggest the bioactive sequence that triggers the anterior pituitary gland to secrete growth hormone (GH) may be located on Sermorelin, the tiniest GHRH fragment.
Like natural GHRH, the peptide has been hypothesized to stimulate the secretion of GH. This GH release all significantly impacts growth, metabolism, and cell proliferation. Two distinct indications prompted its formulation. Each of the two formulations was as follows:
Substantial research has also been done on the possible effects of the peptide in animal research models. Licensed researchers may lawfully obtain the peptide for use in laboratory experiments, and it is already accessible for use in educational and experimental contexts. Visit biotechpeptides.com if you are a licensed professional.
CJC-1295 Peptide: What is it?
A variant of Sermorelin, CJC-1295, is sometimes called modified GRF 1-29 with DAC or DAC: GRF. Improving Sermorelin’s half-life, which is around 10 minutes, was the main objective of these alterations. Its amino acid structure was altered at four locations to make GRF 1-29 more resistant to hydrolysis and oxidation. The substitution of D-alanine for L-alanine at position 2 was believed to greatly enhance the peptide’s resistance to dipeptidyl peptidase-4 (DPP-4), an important enzyme. These changes may cause CJC-1295 no DAC, sometimes called tetrasubstituted or modified GRF 1-29, to have a half-life three times longer than Sermorelin.
Furthermore, the pharmacokinetics of CJC-1295 may be enhanced by modifying it with the drug affinity complex (DAC). The N-terminus of the peptide is joined to the attachment, also called N-epsilon-3-maleimidopropionamide. Due to its increased affinity for plasma proteins, this combination has been theorized to enhance the half-life of CJC-1295 DAC to about eight days.
CJC-1295 vs. Sermorelin
Sermorelin and CJC-1295 are peptide analogs of GHRH, which research suggests may activate the same receptors in the anterior pituitary gland to increase GH production. However, distinct GH responses are believed to be caused by the two peptides because of their drastically varied half-lives. There is no data that Sermorelin or CJC-1295 may raise GH levels during pulses to supraphysiological levels, but there appears to be no change to the pulse frequency. Research on each peptide’s potential to increase GH levels has been the subject of many intriguing research, including the following:
- CJC-1295 research findings implied that the peak GH levels appeared to be within the physiological range, and the peptide seemed to maintain pulsatile secretion while increasing total GH levels. The average growth hormone level was speculated to be almost 150% higher after presentation. Scientists hypothesized that the regimen seemed to have resulted in a sustained rise in mean GH levels by the 28th day, and it was also evaluated as a biweekly presentation (given twice in 14 days).
- Another study asserted that CJC-1295 may increase GH levels for up to a week following the first presentation. Seven days after peptide presentation, the average 12-hour GH levels were speculated to be 46% greater than the average levels before, as suggested by the study’s authors.
- Daily Sermorelin exposure was examined over the course of a six-week study. Based on AUC measurements, this approach seemed to increase mean GH levels by 82%. A further two hours followed each presentation, during which GH concentrations appeared to remain elevated.
Sermorelin Peptide
Investigations purport that Sermorelin may work by boosting the production of growth hormones. Elevated GH levels may potentially enhance lipolysis, the process by which fat cells release their stored fat. Greater gonadotropin-releasing hormone (GH) levels may aid in the reduction of visceral and abdominal fat, as the hormone has been hypothesized to mainly affect these areas.
CJC-1295 Peptide
Data from the aforementioned 12-week study of lipodystrophy in the context of HIV/AIDS was never published. Shorter studies (lasting up to two weeks) have not reported CJC-1295’s impact on weight reduction or muscle mass. Preclinical investigations in GHD mice using CJC-1295 are instead considered.
References
[i] Petersenn, S., & Schulte, H. M. (2000). Structure and function of the growthhormone-releasing hormone receptor. Vitamins and hormones, 59, 35–69. https://doi.org/10.1016/s0083-6729(00)59003-7
[ii] Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 12(2), 139–157. https://doi.org/10.2165/00063030-199912020-00007
[iii] Yuen KCJ. Growth Hormone Stimulation Tests in Assessing Adult Growth Hormone Deficiency. [Updated 2023 Aug 8]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395585/
[iv] Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. (2021).
[v] Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
[vi] Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.
[vii] Scarborough, R., Gulyas, J., Schally, A. V., & Reeves, J. J. (1988). Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. Journal of animal science, 66(6), 1386–1392. https://doi.org/10.2527/jas1988.6661386x
[viii] Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 19(6), 471–477. https://doi.org/10.1016/j.ghir.2009.03.001
THIS IS A SPONSORED PUBLICATION.
Opinions expressed in articles, columns, or any form of content published in this newspaper are solely those of the respective authors or contributors. They do not necessarily reflect the views or opinions of the newspaper, its editorial staff, or its management. The newspaper provides a platform for diverse perspectives and encourages open dialogue on various topics. Readers are encouraged to critically evaluate the viewpoints presented and form their own informed opinions. The newspaper assumes no responsibility or liability for any opinions expressed by individual contributors.
